Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Mesoblast Limited (MESO : NSDQ)

• Company Description    Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. Number of Employees: 81

• Price / Volume Information    Yesterday's Closing Price: $18.04 Daily Weekly Monthly 20 Day Moving Average: 207,677 shares Shares Outstanding: 128.30 (millions) Market Capitalization: $2,314.47 (millions) Beta: 2.14 52 Week High: $21.00 52 Week Low: $9.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.94% 5.12% 12 Week -7.63% -9.12% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL LEVEL 38 55 COLLINS STREET - MELBOURNE,C3 3000 AUS ph: 61-3-9639-6036 fax: 61-3-9639-6030 investors@mesoblast.com http://www.mesoblast.com

• General Corporate Information    Officers Silviu Itescu - Chief Executive Officer Jane Bell - Chair of Board William Burns - Vice Chair; Board Lyn Cobley - Directors Philip Facchina - Directors Peer Information Mesoblast Limited (CORR.) Mesoblast Limited (RSPI) Mesoblast Limited (CGXP) Mesoblast Limited (BGEN) Mesoblast Limited (GTBP) Mesoblast Limited (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 590717401 SIC: 2836 Fiscal Year Fiscal Year End: June Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 128.30 Most Recent Split Date: 1.00 (0.50:1) Beta: 2.14 Market Capitalization: $2,314.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.86 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - - 06/30/25 - - Current Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - 1.99 Quick Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - 1.77 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - -592.00 Book Value 12/31/25 - - 09/30/25 - - 06/30/25 - 4.67 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - 0.22 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - 0.11 Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - 10.18

Powered by Zacks Investment Research ©